Yahoo Web Search

Search results

1. • Small Business - Picayune Item | Picayune Item

     The Picayune Item· 2 days ago

     “Our top priority is executing on our strategy to accelerate the development and delivery of transformative medicines for patients, and we are confident that we can accomplish this mission while ...

2. • ARS Wealth Advisors Group LLC Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

     ETF DAILY NEWS· 2 days ago

     ARS Wealth Advisors Group LLC raised its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 56.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The ...

3. • 

     Three drug-resistant infections in US tied to stem-cell injections in Mexico

     Center for Infectious Disease Research and Policy· 2 days ago

     The first (patient B) was a man from Arizona who developed a right elbow osteoarticular infection...

4. • 

     3 Tried and True Dividend Stocks to Buy for Your Portfolio

     InvestorPlace· 4 days ago

     Picking income stocks can be challenging. It varies year to year, but holding solid income stocks...

5. • MoonLake Immunotherapeutics’ (MLTX) Buy Rating Reiterated at Needham & Company LLC

     ETF DAILY NEWS· 9 hours ago

     Needham & Company LLC reissued their buy rating on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) in a research report sent to investors on Wednesday morning, Benzinga reports ...

6. • 

     Americans Got Drug-Resistant Infections After Stem Cell Treatments in Mexico

     WFMZ Eastern Pennsylvania and Western New Jersey· 2 days ago

     Key Takeaways

7. • Q2 2024 EPS Estimates for Amgen Inc. Reduced by Leerink Partnrs (NASDAQ:AMGN)

     ETF DAILY NEWS· 5 days ago

     Amgen Inc. (NASDAQ:AMGN – Free Report) – Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings estimates for Amgen in a research report issued on Friday, May 3rd. Leerink Partnrs ...

8. • MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes

     GuruFocus.com via Yahoo Finance· 4 days ago

     The company's leading investigational product, sonelokimab, targets IL-17A and IL-17F, which are key drivers of inflammation in conditions such as hidradenitis suppurativa (HS) and ...

9. • Amgen (NASDAQ:AMGN) Rating Increased to Outperform at William Blair

     ETF DAILY NEWS· 7 days ago

     Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by William Blair from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Friday, MarketBeat ...

10. • Amgen (NASDAQ:AMGN) Price Target Cut to $328.00

      ETF DAILY NEWS· 6 days ago

      Amgen (NASDAQ:AMGN – Get Free Report) had its price target reduced by Royal Bank of Canada from $332.00 to $328.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently ...